Caris Life Sciences, Inc. (CAI) Stock Analysis
Healthcare · Biotechnology · NasdaqGS
Caris Life Sciences, Inc. (CAI) posted $812.03M in revenue for fiscal 2025 (up 97.0% year over year), with a net loss of $68.09M, and has compounded revenue about 46.5%/yr over five years, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Caris Life Sciences, Inc.
Caris Life Sciences, Inc. has grown revenue from $258.49M to $812.03M over the last 4 fiscal years, compounding about 46.5% a year. The most recent year was up 97%, so growth is actually accelerating.
Net margin sits at -8.4%, up 60 points year over year on a 66.4% gross margin. It carries about $378.45M of total debt.
At today's valuation the market is pricing in roughly 25.7% annual free-cash-flow growth. The one thing worth a second look in the filings is currently unprofitable.
Synthesised from Caris Life Sciences, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Caris Life Sciences, Inc. revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $258.49M | $306.13M | $412.26M | $812.03M |
| Gross profit | $80.02M | $89.31M | $178.78M | $539.17M |
| Net income | $-320.83M | $-341.42M | $-281.89M | $-68.09M |
| Net margin | -124.1% | -111.5% | -68.4% | -8.4% |
Source: Caris Life Sciences, Inc. SEC filings (10-K).
Caris Life Sciences, Inc.: 1 potential red flag in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Currently unprofitableThe latest fiscal year was a net loss (net margin -8.4%).
What growth is priced into CAI stock?
At today's market cap of $4.96B, Caris Life Sciences, Inc. is priced for free-cash-flow growth of about 25.7% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $66.89M from the FY ending 2025-12-31). This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 4 years of Caris Life Sciences, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track CAI in your portfolio →
Caris Life Sciences, Inc. financial history by metric
About Caris Life Sciences, Inc.
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.
Caris Life Sciences, Inc. — frequently asked questions
What is Caris Life Sciences, Inc.'s revenue?
Caris Life Sciences, Inc. (CAI) reported revenue of $812.03M for fiscal year 2025, up 97.0% from the prior year, according to its SEC filings.
Is Caris Life Sciences, Inc. profitable?
No — CAI reported a net loss of $-68.09M in fiscal 2025.
What is CAI's P/E ratio?
Caris Life Sciences, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Caris Life Sciences, Inc. growing?
CAI's revenue grew at roughly 46.5% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Caris Life Sciences, Inc. have?
As of fiscal year 2025, CAI carried roughly $378.45M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Caris Life Sciences, Inc.'s gross margin?
CAI's gross margin was 66.4% in fiscal 2025 — gross profit of $539.17M on revenue of $812.03M.
What is Caris Life Sciences, Inc.'s market cap?
Caris Life Sciences, Inc. (CAI) has a market capitalization of about $4.96B, based on the latest data in our nightly-refreshed cache.
When does Caris Life Sciences, Inc.'s fiscal year end?
CAI's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into CAI stock?
At today's market cap of $4.96B, Caris Life Sciences, Inc. is priced for free-cash-flow growth of about 25.7% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $66.89M from the FY ending 2025-12-31).
Where does this data come from?
All figures are computed from Caris Life Sciences, Inc.'s official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.